Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

LSB

LakeShore Biopharma Co Ltd

Dec 12 • 04:00PM ET

2.54

Dollar change -0.07
Percentage change -2.68	%

Healthcare • Biotechnology • China • NASD

Peers: VRTX REGN AMGN GILD BIIB ILMN INCY NBIX EXEL LRCX

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	82.69%	Shs Outstand	190.23M	Perf Week	-7.80%
Market Cap	48.47M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	3.30M	Perf Month	-19.62%
Income	-	PEG	-	EPS next Q	-	Inst Own	1.08%	Short Float	0.91%	Perf Quarter	-44.42%
Sales	-	P/S	-	EPS this Y	-	Inst Trans	-19.27%	Short Ratio	0.66	Perf Half Y	-62.65%
Book/sh	0.43	P/B	5.86	EPS next Y	-	ROA	-	Short Interest	0.03M	Perf Year	-53.29%
Cash/sh	1.82	P/C	1.39	EPS next 5Y	-	ROE	-	52W Range	1.88 - 11.20	Perf YTD	-50.29%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-77.32%	Beta	0.81
Dividend TTM	-	Quick Ratio	0.87	Sales past 5Y	-	Gross Margin	-	52W Low	35.11%	ATR (14)	0.45
Dividend Ex-Date	-	Current Ratio	1.13	EPS Y/Y TTM	624.41%	Oper. Margin	-	RSI (14)	42.68	Volatility	10.18% 16.86%
Employees	758	Debt/Eq	0.73	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	52.03
Option/Short	No / Yes	LT Debt/Eq	0.17	EPS Q/Q	-168.14%	Payout	-	Rel Volume	0.16	Prev Close	2.61
Sales Surprise	-8.89%	EPS Surprise	13.58%	Sales Q/Q	-	Earnings	-	Avg Volume	45.09K	Price	2.54
SMA20	-6.35%	SMA50	-15.39%	SMA200	-55.18%	Trades		Volume	7,136	Change	-2.68%

Dec-12-24 07:57PM	LakeShore Biopharma Provides Update on Ongoing Criminal Investigation Involving Former Chairman in China (GlobeNewswire)
Nov-07-24 08:00AM	LakeShore Biopharma Initiates Biologics License Application of PIKA Rabies Vaccine to the Drug Regulatory Authority of Pakistan (GlobeNewswire) +5.99%
Oct-29-24 08:30AM	LakeShore Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement (PR Newswire) -10.66%
Oct-26-24 09:00AM	LakeShore Biopharma Advances with Rabies Vaccine Trial (TipRanks)
Oct-25-24 08:30AM	LakeShore Biopharma Granted Phase III Clinical Trial Approval to Explore Simplified Regimens for YSJA Rabies Vaccine (PR Newswire)
08:30AM	Loading…
Oct-08-24 08:30AM	LakeShore Biopharma Provides Fiscal Half Year 2025 Financial Guidance and Reaffirms Fiscal Year 2025 Financial Guidance (PR Newswire) +21.15%
Sep-27-24 07:00AM	LakeShore Biopharma Announces Results of Extraordinary General Meeting on Share Consolidation (PR Newswire) +7.59%
Sep-10-24 08:00AM	Lakeshore Biopharma to Hold an Extraordinary General Meeting of Shareholders on September 27, 2024 (PR Newswire)
Sep-04-24 08:00AM	LakeShore Biopharma Announces Leadership Transitions (PR Newswire)
Aug-15-24 08:30AM	LakeShore Biopharma Announces Financial Results for Fiscal Year 2024 (PR Newswire)
Jul-05-24 07:00AM	LakeShore Biopharma to Hold an Extraordinary General Meeting on July 25, 2024, Pursuant to Shareholders' Requisition (PR Newswire)
May-24-24 07:30AM	YS Biopharma Announces Name Change to LakeShore Biopharma (PR Newswire) +12.45%
May-21-24 04:15PM	YS Biopharma Announces Results of Extraordinary General Meeting (PR Newswire) -6.23%
May-07-24 04:20PM	YS Biopharma to Hold Extraordinary General Meeting on May 21, 2024 and Announces the Appointment of Interim Chief Executive Officer (PR Newswire) +18.75%
Apr-29-24 08:00AM	YS Biopharma Receives Additional 180 Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule (PR Newswire)
09:10AM	Loading…
Apr-22-24 09:10AM	YS Biopharma Co., Ltd. (NASDAQ:YS) Q3 2024 Earnings Call Transcript (Insider Monkey)
Apr-19-24 11:52AM	YS Stock Earnings: YS Biopharma Co Misses EPS, Beats Revenue for Q3 2024 (InvestorPlace) -15.16%
07:00AM	YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024 (PR Newswire)
Apr-18-24 08:00AM	YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine (PR Newswire) -8.65%
Apr-16-24 08:00AM	YS Biopharma to Report First Nine Months of Fiscal Year 2024 Financial Results on April 19, 2024 (PR Newswire)
Apr-09-24 10:06AM	YS Biopharma's rabies vaccine bests approved competitor in interim phase 3 readout (FierceBiotech.com)
08:00AM	YS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies Vaccine (PR Newswire)
Apr-03-24 08:00AM	YS Biopharma Announces Full Repayment of US$40,000,000 Loan Facility (PR Newswire) +12.42%
Mar-05-24 08:00AM	YS Biopharma Announces Board Changes and Strategic Leadership Appointments in Chinese Subsidiaries (PR Newswire) +32.03%
Feb-22-24 05:00PM	YS Biopharma Announces Results of Extraordinary General Meeting held on February 22, 2024 (PR Newswire)
Feb-18-24 04:30AM	/C O R R E C T I O N -- YS Biopharma Co., Ltd./ (PR Newswire)
Feb-16-24 08:20PM	YS Biopharma Announces Results of Extraordinary General Meeting and Responds to False Statements about the Meeting (PR Newswire)
05:36PM	Shareholders Led by Yi Zhang Announce Successful Results of Removal of Directors and Election of New Directors of YS Biopharma Co., Ltd. (PR Newswire)
Feb-14-24 08:00AM	YS Biopharma to Hold an Extraordinary General Meeting on February 22, 2024 pursuant to a Shareholder Requisition to Enhance Corporate Governance (PR Newswire)
07:50AM	YS Biopharma Announces Appointment of New Directors (PR Newswire)
08:50AM	Loading…
Feb-12-24 08:50AM	YS Biopharma Responds to a Notice of Extraordinary General Meeting of Shareholders of YS Biopharma Co., Ltd. (PR Newswire)
Feb-09-24 06:30AM	YS Biopharma Announces US$40 Million Private Placement Financing (PR Newswire)
Feb-08-24 06:10PM	Shareholders of YS Biopharma Announce an Extraordinary General Meeting (PR Newswire)
Jan-24-24 04:00PM	Diamond Equity Research Releases Update Note on YS Biopharma Co., Ltd. (NASDAQ: YS) (GlobeNewswire) -9.56%
Jan-22-24 10:51PM	YS Stock Earnings: YS Biopharma Co Misses EPS, Misses Revenue for Q2 2024 (InvestorPlace)
05:00PM	YS Biopharma Announces Unaudited Financial Results for the First Half of Fiscal Year 2024 (PR Newswire)
Jan-08-24 08:00AM	YS Biopharma Announces Changes to its Board Committees (PR Newswire) +7.00%
Dec-20-23 04:30PM	YS Biopharma Responds to Unauthorized Press Release Regarding Extraordinary General Meeting (PR Newswire) -11.76% +13.33%
04:15PM	/DISREGARD RELEASE: YS Biopharma/ (PR Newswire)
08:56AM	YS Biopharma Co., Ltd. to Hold Extraordinary General Meeting on December 28, 2023 (PR Newswire)
Nov-14-23 08:30AM	Noble Capital Markets Initiates Coverage on YS Biopharma With Outperform Rating and US$5.25 Price Target (PR Newswire)
Oct-31-23 08:30AM	YS Biopharma Announces Completion of Subject Enrollment in Pivotal Phase 3 Clinical Trial of PIKA Rabies Vaccine (PR Newswire)
Oct-26-23 08:30AM	YS Biopharma Announces Receipt of Nasdaq Notice (PR Newswire) -15.06%
Oct-10-23 08:00AM	UPDATE - Diamond Equity Research Releases Update Note on YS Biopharma Co., Ltd. (NASDAQ: YS) (GlobeNewswire)
Sep-26-23 08:30AM	YS Biopharma Announces First Subject Enrollment in Pivotal Phase 3 Clinical Trial of PIKA Rabies Vaccine (PR Newswire)
Sep-20-23 08:00AM	Diamond Equity Research Releases Update Note on YS Biopharma Co., Ltd. (NASDAQ: YS) (GlobeNewswire)
Sep-15-23 08:30AM	YS Biopharma Granted Patent in the U.S. for Immunotherapy Targeting Chronic Hepatitis B Virus Infection (PR Newswire)
Sep-05-23 08:30AM	YS Biopharma to Participate in Participate in Citi's 18th Annual Biopharma Conference (PR Newswire)
Aug-24-23 04:15PM	YS Biopharma Announces Purchase of Shares by Company Officers (PR Newswire) +60.46%
Aug-17-23 08:00AM	Diamond Equity Research Initiates Coverage on YS Biopharma Co., Ltd. (NASDAQ: YS) (GlobeNewswire) -6.36%
Aug-15-23 05:00PM	YS Biopharma Announces Unaudited Financial Results for the First Quarter of Fiscal Year 2024 (PR Newswire) -9.09%
Aug-10-23 04:30PM	YS Biopharma to Report First Quarter Fiscal Year 2024 Financial Results on August 15, 2023 (PR Newswire)
Jul-26-23 05:00PM	YS Biopharma Announces Financial Results for Fiscal Year 2023 Ended March 31, 2023 (PR Newswire)
Jul-21-23 04:30PM	YS Biopharma to Report Financial Results for Fiscal Year 2023 on July 26, 2023 (PR Newswire)
Jun-09-23 08:00AM	Diamond Equity Research to Host Global Select Emerging Growth Invitational Virtual Investor Conference on June 13th, 2023 (GlobeNewswire)
Jun-08-23 01:45PM	YS Biopharma (NASDAQ:YS) shareholders have endured a 80% loss from investing in the stock a year ago (Simply Wall St.)
Jun-01-23 08:30AM	YS Biopharma's PIKA Rabies Vaccine Receives Phase 3 Clinical Trial Approval From Philippines FDA (PR Newswire) +10.60%
May-18-23 08:25AM	YS Biopharma to Participate in the Virtual Benchmark Healthcare House Call Conference on May 23, 2023 (PR Newswire)
May-16-23 07:00AM	YS Biopharma's PIKA Rabies Vaccine Receives Phase 3 Clinical Trial Approval in Pakistan (PR Newswire)
Apr-18-23 07:00AM	YS Biopharma Announces Record Vaccine Revenues and Preliminary Financial Results for FY2023 Ended March 31, 2023 (PR Newswire)
Mar-27-23 06:00AM	YS Biopharma's PIKA Recombinant COVID-19 Vaccine Demonstrates Superior Antibody Neutralization Responses Compared to Inactivated COVID-19 Vaccine in Phase II Head-to-Head Clinical Study (PR Newswire) -36.95%

LakeShore Biopharma Co., Ltd. engages in the provision of discovering, developing, manufacturing, and commercializing vaccines and therapeutic biologics for infectious diseases and cancer. It focuses on developing PIKA technology platform. It operates through the People's Republic of China and Other Countries or Regions. The company was founded by Yi Zhang on November 16, 2020 and is headquartered in Beijing, China.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LSB

LakeShore Biopharma Co Ltd

Upgrade your FINVIZ experience